{
    "nct_id": "NCT05197049",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease",
    "inclusion_criteria": "* Diagnosis of Crohn's disease (CD) of at least 3 months in duration\n* Have moderate to severe CD as assessed by CDAI, stool frequency, and abdominal pain score, and Simple Endoscopic Score for Crohn's disease (SES-CD).\n* Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current diagnosis of ulcerative colitis or indeterminate colitis\n* Complications of Crohn's disease that require surgical intervention or confound efficacy assessments\n* Unstable doses of concomitant Crohn's disease therapy",
    "miscellaneous_criteria": ""
}